In the field of basic and clinical neurosciences, it is important to develop a method for easy delivery and persistent expression of transgene in central neurons. We firstly generated lentiviral vectors with five kinds of neuron-specific promoters, such as synapsin I (SYN), calcium/calmodulindependent protein kinase II, tubulin alpha I, neuron-specific enolase and platelet-derived growth factor beta chain promoters and then novel hybrid promoters by fusing cytomegalovirus enhancer (E) to those neuron-specific promoters. Neuron-specific expression of green fluorescent protein (GFP) with those promoters was examined in vivo by injecting the lentiviral vectors into the rat neostriatum, thalamus and neocortex. Among all the promoters, SYN promoter displayed the highest specificity for neuronal expression in all the regions examined (more than 96%). Although GFP production by the hybrid promoters was about 2-4 times larger than the non-enhanced promoters, the neuronal specificity was significantly decreased in most cases. However, the neuronal specificity of E/SYN hybrid promoter exhibited the least decrease only in the thalamus. Furthermore, the transcriptional activity and neuronal specificity of E/SYN promoter were sustained for up to 8 weeks. Thus, lentivirus with E/SYN promoter is the best vector for strong persistent expression in neurons.
Introduction
Gene delivery to the central nervous system with recombinant viral vectors have aroused interest in the field of basic and clinical neurosciences, and many kinds of viral vectors have been developed for investigation of neuronal morphology, gene function, modeling of human diseases and therapeutic applications. 1, 2 Among available viral vectors, lentiviral vectors offer unique advantages of stably integrating transgene into the genome of dividing and non-dividing cells, and providing the basis for sustained gene expression without any toxicity and immune response. Lentiviral vectors are, therefore, considered to be the most appropriate ones for experiments requiring long-term gene expression and gene therapeutic applications.
Self-inactivating and replication-defective lentiviral vectors, derived from human immunodeficiency virus type 1 (HIV-1), have been developed for transduction of mammalian cells. [3] [4] [5] [6] These vectors are pseudotyped with vesicular stomatitis virus G-protein (VSV-G), and VSV-G achieves a broad transduction spectrum. 7 Many gene delivery vectors have used viral promoters, particularly cytomegalovirus (CMV) or rous sarcoma virus promoter, because they have high transcription activities in all the infected cells whatever their cell types are. Taken together, VSV-G-pseudotyped lentiviral vectors with CMV promoter express transgene in not only neuronal but also glial cells in the central nervous system [3] [4] [5] 8 Thus, it is indispensable to utilize neuron-specific promoters for stable neuron-specific expression of transgene with VSV-G-pseudotyped lentiviral vectors.
Many kinds of neuron-specific promoters have been developed and applied to transgenic animals and viral vectors. 9 As lentiviral vectors cannot accept large genetic sequences (up to 10 kb between the long terminal repeats), we selected relatively small promoters. In the present study, we used five kinds of neuron-specific promoters; human synapsin I (SYN), 10 mouse calcium/ calmodulin-dependent protein kinase II (CaMKII), 11 rat tubulin alpha I (Ta1), 12 rat neuron-specific enolase (NSE) 13 and human platelet-derived growth factor-beta chain (PDGF) promoters.
14 Although these promoters are known to be specific for neuronal expression, the transcriptional activities are much weaker than those of viral promoters such as CMV promoter. In the present study, we generated novel hybrid promoters by a combination of CMV enhancer and the neuron-specific promoters listed above to enhance promoter activities, and then characterized their neuronal specificities and transcriptional activities in the rat neostriatum, thalamic nuclei and cerebral cortex, using enhanced green fluorescent protein (GFP) as a reporter protein. The purpose of the present study is to explore the best promoter for strong, persistent and specific expression of transgene in neurons with VSV-G-pseudotyped lentiviral vectors.
Results
GFP expression by neuron-specific and enhanced neuron-specific promoters in the rat neostriatum, thalamus and neocortex
We generated 11 kinds of VSV-G-pseudotyped lentiviral vectors, which express GFP under CMV, neuron-specific and enhanced neuron-specific promoters ( Figure 1 , Table  1 ). At 1 week after injection of the lentiviral vectors into the rat neostriatum, ventrobasal thalamic nuclei and somatosensory cortex, GFP was visualized by immunoperoxidase staining (diaminobenzidine-4HCl (DAB) reaction). GFP expression driven by CMV promoter was observed in not only neuronal but also glial cells (arrowheads and insets in Figure 2a1 -a3). The immunoreactivity was very intense and detected in cell bodies as well as distal dendrites (Figure 2a1-a3) . Under SYN promoter, GFP expression was found only in neurons, but the immunoreactivity was conspicuously weak, especially in the thalamus (Figure 2b1-b3) . Using E/SYN promoter, intense immunoreactivity was observed predominantly in neurons, and distal dendrites were also well visualized (Figure 2c1-c3) . These results indicate that the neuronal specificities of SYN and E/SYN promoters are higher than that of CMV promoter, and the expression levels of CMV and E/SYN promoters are stronger than that of SYN promoter. In the other neuronspecific promoters, the immunoreactivity for GFP also became more intense but neuronal specificity was Figure 1 Construction of pLenti6-Pro-GFP-WPRE. We firstly introduced 11 kinds of promoters (CMV, neuron-specific and enhanced neuron-specific promoters), GFP and WPRE into pBSII SK (a), and then KpnI-to-NotI fragment was inserted into the KpnI/ NotI sites of pENTRIA (b). The insert (Pro-GFP-WPRE) was transferred pLenti6 with LR recombination reaction, and resulting to pLenti6-Pro-GFP-WPRE (c). CMV-E, the enhancer region of human cytomegalovirus promoter; GFP, enhanced green fluorescence protein; LTR, long-terminal repeat; f, HIV-1 packaging signal; Pro, promoter, RPE, HIV-1, Rev response element; WPRE, woodchuck hepatitis virus post-transcriptional element. See text for further detail. Abbreviations: CaMKII, calcium/calmodulin-dependent protein kinase II; CMV, cytomegalovirus; NSE, neuron-specific enolase; PDGF, platelet-derived growth factor; SYN, synapsin; TaI, tubulin alpha I. We amplified CMV promoter and five kinds of neuron-specific promoters by polymerase chain reaction with the primer sets indicated above, and inserted them into plasmid vectors. We further developed novel hybrid promoters by fusing CMV enhancer to those neuron-specific promoters. See text for further details.
Lentivirus with enhanced neuron-specific promoters H Hioki et al decreased to some extent after addition of CMV enhancer. Transduction efficiencies of neuron-specific and enhanced neuron-specific promoters appeared somewhat lower than that of CMV promoter, this is probably because most of glial cells did not express GFP under those promoters even though transgene was integrated into their genomes. In addition, we observed no remarkable differences of GFP-expressing cell numbers between neuron-specific and enhanced neuron-specific promoters. In the following experiments, we quantitatively analyzed neuronal specificities and expression strength of all promoters listed in Table 1 .
Neuronal specificity
At 1 week after injection of lentiviral vectors with all promoters listed in Table 1 , we randomly selected 100-200 GFP-expressing cells around the injection sites in the rat neostriatum, ventrobasal thalamic nuclei and somatosensory cortex, and then examined whether or not these cells might show immunoreactivity for NeuN (Figure 3 ; in the neostriatum). We compared neuronal specificities between promoters with or without CMV enhancer by using the two-tailed Student's t-test ( Figure  4a ). After addition of CMV enhancer, the neuronal specificities of CaMKII, Ta1 and NSE promoters exhibited a statistically significant decrease at all the brain regions examined, whereas that of PDGF promoter did not display any significant change. SYN promoter showed the highest specificity for neuronal expression among all the promoters (more than 96%), whereas E/SYN promoter exhibited the least decrease in neuronal specificity only in the thalamic nuclei (P ¼ 0.042). However, the specificity of E/SYN promoter remained relatively high at all the brain regions compared with the other enhanced neuron-specific promoters. We further examined time course of neuronal specificities from 3 days to 8 weeks after injection of lentiviral vectors with CMV, SYN or E/SYN promoter into the neostriatum (Figure 4b ). The neuronal specificities of these promoters showed no remarkable changes and seemed constant throughout 8 weeks in the neostriatum; the specificities of SYN and E/SYN promoters stayed around 98%, whereas that of CMV promoter remained about 50%.
Time course of GFP expression levels
To determine time course of GFP expression levels, we injected lentiviral vectors with SYN or E/SYN promoter into the rat neostriatum, allowed the animals to survive Table 1 at 1 week after the injection. Lentivirus with enhanced neuron-specific promoters H Hioki et al
Comparisons of GFP expression levels by neuronspecific and enhanced neuron-specific promoters At 1 week after injection of lentiviral vectors with all promoters listed in Table 1 , I IF and I IF V were measured in the infected neurons of the rat neostriatum, ventrobasal thalamic nuclei and layer II/III of somatosensory cortex (Figure 7a and b), as described before (Figure 5a ). We first compared I IF between neuron-specific and enhanced neuron-specific promoters (Figure 7a ). I IF was increased by 1.4-3.6-fold in all the enhanced promoters at all the brain regions examined (two-tailed Student's t-test, n ¼ 15, 7.9 Â 10 À16 ppp5.0 Â 10 À3 ). We further compared I IF between CMV and all the hybrid promoters by one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test. E/Ta1 promoter displayed higher intensity than CMV promoter in the neostriatum, whereas E/CaMKII and E/PDGF promoters exhibited lower intensities than CMV promoter in the thalamus and neocortex. No significant differences were detected between CMV and the other enhanced promoters in the other regions examined. I IF was generally weaker in the thalamus than in the neostriatum and neocortex. However, this does not mean that the promoter activity was weak in the thalamus, because I IF did not reflect the total amount of GFP in single neurons especially when compared with small and large neurons, such as somatic volumes of neostriatal and thalamic neurons (7.771.6 (10 3 Â mm Thus, to estimate promoter activity in neurons of different sizes, we calculated I IF V from average I IF and somatic volume (V). I IF V produced by all the hybrid promoters was 1.6-3.8 times higher than non-enhanced promoters at all the brain regions examined (Figure 7b ,
). Multiple comparison tests between CMV and all the hybrid promoters were also performed by one-way ANOVA followed by Dennett's post hoc test. E/Ta1 promoter was stronger than CMV promoter in the neostriatum, whereas E/CaMKII promoter in the thalamus and E/PDGF promoter in the thalamus and neocortex were weaker than CMV promoter. No significant differences were detected between CMV and the other enhanced promoters in the other regions examined. I IF V in the neocortex was larger than those in the neostriatum and thalamus, suggesting that the transcriptional activity was generally stronger in the neocortex.
Discussion
We developed novel hybrid promoters by fusing CMV enhancer to neuron-specific promoters, and quantitatively examined their characteristics in vivo with VSV-Gpseudotyped lentiviral vectors derived from HIV-1. After addition of CMV enhancer to neuron-specific promoters, the neuronal specificities of most promoters were significantly decreased, although the expression levels were increased by about two-to four-fold in all the hybrid promoters. Among all the hybrid promoters, the neuronal specificity of E/SYN promoter remained comparatively high, and the expression levels of E/SYN promoter was almost the same as that of CMV promoter at all the brain regions examined. These results lead to the conclusion that E/SYN promoter might be the most appropriate one to express a gene of interest in neurons efficiently and specifically.
Technical consideration: quantification of promoter activity
Transcriptional activity of promoter has been analyzed using several reporter enzymes; chloramphenicol acetyltransferase, luciferase, alkaline phosphatase and b-galactosidase. 15 Recently, it was demonstrated that GFP also had all the essential properties of a quantitative Lentivirus with enhanced neuron-specific promoters H Hioki et al reporter protein and concluded that GFP is reliable and useful one for analysis of promoter activity by measuring fluorescence intensity. 16 As GFP has the advantage that promoter activity can be easily monitored in single cells in sections, we selected GFP as a reporter protein in the present study.
To analyze promoter activity precisely, total amount of GFP should be wholly calculated in single cells. Morphology of neuronal cells, however, is so complicated that it is impractical to completely estimate total amount of GFP in single cells in sections. In the present study, we estimated transcriptional activities by calculating I IF V from average immunofluorescence intensity per pixel (I IF ) and somatic volume (V). Although this estimation did not include GFP in dendrites and axons, I IF was obviously weak in those processes (Figure 5a,  Figure 6b , b 0 and d, d 0 ). Thus, the underestimation of GFP amount was considered to be not so high in the present study. Actually, GFP-IF was not detected in axonal structures, and most GFP-IF was localized in somata. Furthermore, GFP-IF in somatic volume reflected about 80% of GFP produced by neurons, suggesting that the total GFP produced by neurons might be predicted by calculating IV (see Supplementary Figure 1 
online).
Under SYN and E/SYN promoters, I NF and I NF V were linearly increased from 1 to 8 weeks, whereas I IF and I IF V became saturated by 8 weeks after viral injection into the neostriatum ( Figure 5 ). To investigate this discrepancy, we compared I NF and I IF from identical neurons, and analyzed their correlation at 1 or 2 weeks after viral injection into the neostriatum (Figure 6 ). When I NF was about within 60 (U) in the present study, GFP-NF was linearly amplified by immunofluorescence staining but not at over 60 (U). This indicates that immunofluorescence staining linearly reflects the amount of antigen within at most 1 week in the present study. 
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The effect of CMV enhancer
After addition of CMV enhancer to neuron-specific promoters, their characteristics were markedly changed; neuronal specificities were decreased and transcriptional activities were drastically enhanced. Although, it has not yet been answered how the enhancer altered characteristics of these neuron-specific promoters, a considerable number of studies have been made on the functional Lentivirus with enhanced neuron-specific promoters H Hioki et al mechanisms of CMV enhancer over the past few decades. Several distinct sets of cellular transcription factors bind to and stimulate the enhancer, so that it functions as a strong transcriptional enhancer. 17 Thus, it can be assumed that transcriptional activities were augmented but the neuronal specificities were loosened in the hybrid promoters owing to such a functional feature of CMV enhancer.
The potential of CMV enhancer for hybrid approach has been demonstrated by several reports. CMV enhancer/chicken beta-actin promoter is a very strong one and has been widely applied to transgenic animals and viral vectors. 18 A hybrid promoter by fusing CMV enhancer to PDGF promoter was also reported, and this hybrid promoter significantly augmented transgene expression in neurons in vitro and in vivo, using plasmid vectors, recombinant adeno-associated virus vectors and baculovirus-derived vectors. [19] [20] [21] Moreover, the transcriptional activity of glial fibrillary acidic protein promoter was strikingly increased after addition of CMV enhancer, whereas the astrocytic specificity of the promoter remained high. 22 These reports and the present results suggest that a hybrid approach might be effective in improvement on transcriptional activities of cellular promoters.
Time course of GFP expression
We observed time course of transcriptional activities and neuronal specificities of SYN and E/SYN promoters from 3 days to 8 weeks after viral injection into the neostriatum. Surprisingly, GFP-NF linearly increased even up to 8 weeks in both the promoters, indicating that the transcriptional activities of these promoters can be maintained at least during 8 weeks. Furthermore, the neuronal specificities of both the promoters displayed no remarkable changes throughout 8 weeks, suggesting that neuronal specificity is independent of time course and amount of GFP products for at least 8 weeks. It is noteworthy that although the transcriptional activity of E/SYN promoter was almost as strong as that of CMV promoter, the transcriptional activity and neuronal specificity remained very high for up to 8 weeks. As persistent transcriptional activity and neuronal specificity are crucial issues for in vivo modeling and gene therapy of human neurodegenerative diseases, a combination of lentiviral vectors and E/SYN promoter is suitable for strong persistent gene expression in central neurons.
Prospects of VSV-G-pseudotyped lentiviral vectors with E/SYN promoter
Lentiviral vectors are now considered to be a most promising tool for experiments requiring long-term gene expression and gene therapeutic applications in the central nervous system [23] [24] [25] by the following reasons: lentiviral vectors (1) integrate transgene into the genome of dividing and non-dividing cells; (2) enable us to express transgene permanently in the infected cells without immune response; (3) can be directly delivered to specific brain region by local injection; and (4) can be applied to mammalian species other than rats at anytime during the lifespan of the animals. Actually, lentiviral vectors have provided new strategies for in vivo modeling and treatments of human neurodegenerative diseases such as Parkinson's disease (PD). 26, 27 In the modeling of PD, for example, mutated alphasynuclein was overexpressed in the rat substantia nigra by local injection of VSV-G-pseudotyped lentiviral vector with phosphoglycerate kinase (PGK) promoter. 28 After the viral injection, most of nigral dopaminergic neurons were selectively abolished and the immunoreactivity for tyrosine hydroxylase (TH) was significantly decreased, indicating that an adult onset model of PD can be generated by direct stereotaxic injection of viral vectors expressing a gene linked to PD. However, as PGK promoter is one of the ubiquitous promoters, transgene is generally expressed in both neuronal and glial cells. Thus, it cannot be denied that the genetic model of PD was affected by overexpression of mutated alphasynuclein in glial cells. As alpha-synuclein is produced only in neurons, the expression should be restricted in neurons for establishing more sophisticated animal models and analyzing pathogenetic mechanisms more precisely.
It was further reported that VSV-G-pseudotyped lentivirus can achieve functional improvement in a rat model of PD. 29 In the experiment, nigral dopaminergic neurons were damaged by administration of 6-hydroxydopamine, and then TH, aromatic amino acid dopa decarboxylase and GTP cyclohydrolase 1 were delivered into the dopamine-denervated striatum, using lentivirus with CMV promoter. After the viral injection, sustained transgene expression, dopamine production and functional improvement were observed, suggesting that this method has the potential for gene therapy of late-stage PD patients. Although VSV-G-pseudotyped lentiviral vectors have been also developed for gene therapy experiments of the other neurodegenerative diseases, ubiquitous promoters were employed to express transgene in almost all the cases. For avoidance of unexpected side effects caused by ectopic gene expression, it is desirable to use tissue-specific promoters.
In the present study, we demonstrated that E/SYN hybrid promoter is highly neuron-specific and has strong transcriptional activity. Thus, E/SYN promoter may replace ubiquitous promoters for gene transductions of neurons, and VSV-G-pseudotyped lentivirus with E/SYN promoter may accelerate the experiments for in vivo modeling and treatments of human neurodegenerative diseases.
Concluding remarks
In summary, E/SYN promoter was proved to be an excellent one for gene expression in neuronal tissues by the following reasons; (1) the neuronal specificity was relatively high compared with the other hybrid promoters, and kept around 98% in the neostriatum during 8 weeks; (2) the transcriptional activity was almost as strong as that of CMV promoter, and kept for at least 8 weeks; and (3) the length of E/SYN promoter is short (769 bp), which enable us to apply the E/SYN promoter to many kinds of viral vectors. We expect that this novel E/SYN promoter will be a useful tool in the field of basic and clinical neurosciences.
Materials and methods
The experiments were conducted in accordance with the Committees for Animal Care and Use of the Graduate Lentivirus with enhanced neuron-specific promoters H Hioki et al School of Medicine at Kyoto University, and for Recombinant DNA Study in Kyoto University. All efforts were made to minimize animal suffering and the number of animals used.
Plasmids construction
The lentiviral vector was derived from HIV-1 (Invitrogen, Carlsbad, CA, USA), and constructed as follows. We used human CMV (nucleotides 1-589 of gb: U57609, GenBank) promoter and five kinds of neuron-specific promoters for human SYN, mouse CaMKII, rat Ta1 (a gift from Dr Miller), rat NSE (a gift from Dr Forss-Petter and Dr Sutcliffe) and human PDGF (a gift from Dr Sasahara and Dr Collins) promoters (Table 1) . These six promoters, enhanced GFP (Clontech, Palo Alto, CA, USA) and woodchuck hepatitis virus posttranscriptional regulatory element (WPRE; nucleotides 1093-1684 of gb: U57609; a gift from Dr Hope 30 ) were amplified by polymerase chain reaction (PCR), and inserted into HincII, EcoRV and SmaI sites of pBluescript II SK (+) (pBSII SK; Stratagene, La Jolla, CA, USA), respectively ( Figure 1a ). To generate novel hybrid promoters by a combination of CMV enhancer and neuron-specific promoters (Table 1) , the enhancer region of CMV promoter was firstly amplified by PCR with the following primers: 5 0 -TAGTTATTAA TAGTAATCAA-3 0 and 5 0 -TTTTCACGTGCCATGGTAA TAGCGATGACT-3 0 (PmaCI site underlined), and subcloned into HincII site of pBSII SK. Then, five kinds of neuron-specific promoters (Table 1) , GFP and WPRE were inserted into the PmaCI, EcoRV and SmaI sites, respectively (Figure 1a) . These totally eleven constructs were confirmed by sequencing and named as pBSII-SKPro-GFP-WPRE. To generate a Gateway entry vector, a KpnI-to-NotI fragment from pBSII-SK-Pro-GFP-WPRE was inserted into the KpnI/NotI sites of pENTR1A (Invitrogen, Figure 1b) . Then, the insert from the entry vector (Pro-GFP-WPRE) was transferred to the destination vector pLenti6/BLOCK-iT-DEST by homologous recombination with LR clonase (Invitrogen), resulting in pLenti6-Pro-GFP-WPRE (Figure 1c ).
Production and concentration of VSV-G-pseudotyped lentivirus
The production of VSV-G-pseudotyped lentivirus was performed according to the manufacturer's instructions, ViraPower Lentiviral Expression System (Invitrogen). The destination plasmid pLenti6-Pro-GFP-WPRE was cotransfected with the mixture of the packaging plasmids (pLP1, pLP2 and pLP/VSVG; Invitrogen) into the 293FT producer cell line (Invitrogen), using Lipofectamine 2000 (Invitrogen). The medium was replaced at 8 h after transfection with Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. After 60 h from transfection, the viral particles in the culture supernatant were collected, filtered through 0.45-mm filters (Millipore, Corning, NY, USA) following low speed centrifugation (3000 g, 15 min), and then concentrated with Centricon Plus-20 (Millipore). Viral titers (transducing units/ml) were determined by transduction of 293FT cells with serial dilutions of the viral solution and colony counting after blasticidin selection, and adjusted to 1.0 Â 10 6 TU/ml. The virus solution was stored in aliquots at À801C until use for delivery to brain tissues. This viral vector was replication deficient and had the least chance for production of parent viral particles in the infected cells.
Injection of viruses, fixation and immunoperoxidase staining
Forty-one adult male Wistar rats (250-300 g; Japan SLC, Shizuoka, Japan) were deeply anesthetized with chloral hydrate (35 mg/100 g body weight). The virus (1.0 ml of 1.0 Â 10 6 TU/ml) was stereotaxically injected by pressure through a glass micropipette attached to Picospritzer III (General Valve Corporation, East Hanover, NJ, USA) into the rat neostriatum, ventrobasal thalamic nuclei and somatosensory cortex. The rats were allowed to survive from 3 days to 8 weeks after the injection.
The rats were deeply anesthetized again with chloral hydrate (70 mg/100 g body weight), and perfused transcardially with 200 ml of 5 mM phosphate-buffered 0.9% (w/v) saline (PBS; pH 7.4). The rats were further perfused for 30 min with 200 ml of 3% (w/v) formaldehyde, 75%-saturated picric acid and 0.1 M Na 2 HPO 4 (pH 7.0; adjusted with NaOH). The brains were removed, cut into several blocks and post-fixed with the same fixative above for 8 h at 41C. After cryoprotection with 30% (w/w) sucrose in PBS, the blocks were cut into 30-mm-thick sections on a freezing microtome. Some sections were mounted onto gelatinized glass slides without immunostaining, and coverslipped with 50% (v/v) glycerol and 2.5% (w/v) triethylenediamine (antifading reagent) in PBS.
Some sections were incubated overnight with 0.2 mg/ ml affinity-purified rabbit antibody to GFP, 31 and then for 1 h with 10 mg/ml biotinylated anti-(rabbit immunoglobulin (Ig)G) donkey antibody (Chemicon, Temecula, CA, USA). The incubation was carried out at room temperature in PBS containing 0.3% (v/v) Triton X-100, 0.25% (w/v) l-carrageenan and 1% (v/v) donkey serum (PBS-XCD) and followed by a rinse with PBS containing 0.3% (v/v) Triton X-100 (PBS-X). The sections were further incubated for 1 h with avidin-biotinylated peroxidase complex (ABC-Elite; Vector Laboratories, Burlingame, CA, USA) in PBS-X. After a rinse with PBS-X, the sections were reacted for 20-40 min with 0.02% (w/v) DAB and 0.001% (v/v) H 2 O 2 in 50 mM Tris-HCl (pH 7.6), mounted onto gelatinized glass slides, dehydrated in ethanol series, cleared in xylene and coverslipped. Photographs were taken by the digital camera QICAM (QIMAGING, Burnaby, BC, Canada), modified (720% contrast enhancement) in software Canvas 8 (ACD Systems, Saanichton, BC, Canada) and saved as 8-bit TIFF files.
Double immunofluorescence labeling
The brain sections, which were obtained as described above, were incubated overnight in PBS-XCD with a mixture of 1 mg/ml anti-GFP rabbit antibody 31 and 1 mg/ ml anti-NeuN mouse antibody (Chemicon). After a rinse with PBS-X, the sections were incubated for 2 h with 5 mg/ml AlexaFluor 488-conjugated anti-(rabbit IgG) goat antibody and 5 mg/ml AlexaFluor 647-conjugated anti-(mouse IgG) goat antibody (Molecular Probes, Eugene, OR, USA). The sections were mounted onto gelatinized glass slides and coverslipped with 50% (v/v) glycerol and 2.5% (w/v) triethylenediamine (antifading reagent) in PBS. Digital pseudocolor images were Lentivirus with enhanced neuron-specific promoters H Hioki et al captured by confocal laser-scanning microscope LSM 5 Pascal (Carl Zeiss, Oberkochen, Germany) with optical slice thickness (Pinhole corresponding to 1 airy unit), using a Â 40 objective lens (Plan-NEOFLUAR, NA ¼ 0.75, Carl Zeiss). AlexaFluor 488 and 647 were excited with 488-and 633-nm laser beams and observed through 510-530-and X650-nm emission filters, respectively. The images were modified (720% contrast enhancement) in software Canvas 8 and saved as 8-bit TIFF files.
Measuring fluorescence intensity
GFP-IF or GFP-NF was observed under confocal laserscanning microscope LSM 5 Pascal as described above.
The digital images were captured in the rat neostriatum, ventrobasal thalamic nuclei and layer II/III of somatosensory cortex and saved as 12-bit TIFF files (without contrast enhancement). We measured average intensity of florescence per pixel (I (U)), sectional area (A (mm 2 )) with software ImageJ (http://rsb.info.nih.gov/ij). To keep the condition for taking digital images constant, we adjusted laser power, gain and offset each time by monitoring intensity of fluorescence beads (#F-14791, Molecular Probes).
Statistics
Two-tailed Student's t-test, one-way ANOVA followed by Dennett's post hoc test, and linear or logistic regression analysis were performed by using software Excel (Microsoft Corporation, Redmond, WA, USA), Prism (Graphpad Software Inc., San Diego, CA, USA) and DeltaGraph (RockWare Inc., Golden, CO, USA), respectively.
